Bank of New York Mellon’s Cognition Therapeutics CGTX Stock Holding History

Bank of New York Mellon’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.5K	Hold	13,462	–	–	﹤0.01%	4275
2026 Q1	$10.2K	Buy	+13,462	New	+$15.7K	﹤0.01%	4186
2024 Q1	–	Sell	-17,795	Closed	-$32.9K	–	4184
2023 Q4	$32.9K	Hold	17,795	–	–	﹤0.01%	4195
2023 Q3	$25.6K	Hold	17,795	–	–	﹤0.01%	4228
2023 Q2	$32.6K	Buy	+17,795	New	+$37.7K	﹤0.01%	4235

Other funds holding CGTX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return

Corient Private Wealth Miami, Florida $78.6B AUM 28.08% 1-Year Est. Return

Bank of New York Mellon's CGTX Position: Q2 2026 in Review

Bank of New York Mellon held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 13,462 shares worth $15.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4275.

Bank of New York Mellon first reported a position in CGTX in Q2 2023 and has held it in 5 quarters since. The position peaked at $32.9K in Q4 2023. 40 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Bank of New York Mellon held 13,462 shares of Cognition Therapeutics worth $15.5K as of Q2 2026.
Bank of New York Mellon left its Cognition Therapeutics share count unchanged in Q2 2026.
Cognition Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4275 holding.
Bank of New York Mellon first reported a position in Cognition Therapeutics in Q2 2023 and has held it in 5 quarters since.
Bank of New York Mellon's Cognition Therapeutics position peaked at $32.9K in Q4 2023.
40 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.